<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.0" xml:lang="HR" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-142-85</article-id>
<article-id pub-id-type="doi">10.26800/LV-142-3-4-14</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Guidelines</subject></subj-group>
</article-categories>
<title-group>
<article-title>Smjernice za osobe sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u i zdravstvene djelatnike koji skrbe o oboljelima od &#x0161;e&#x0107;erne bolesti u Republici Hrvatskoj u vrijeme COVID-19 pandemije Radne skupine Hrvatskog dru&#x0161;tva za dijabetes i bolesti metabolizma Hrvatskoga lije&#x010D;ni&#x010D;kog zbora</article-title>
<trans-title-group xml:lang="en">
<trans-title>Recommendations of the Working group of the Croatian Society for Diabetes and Metabolic Disorders of the Croatian Medical Association for people with diabetes and healthcare professionals in the Republic of Croatia during COVID-19 pandemic</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2901-0646</contrib-id><name><surname>Raheli&#x0107;</surname><given-names>Dario</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mati&#x0107;</surname><given-names>Tomas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Skelin</surname><given-names>Marko</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Klobu&#x010D;ar Majanovi&#x0107;</surname><given-names>Sanja</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bakula</surname><given-names>Miro</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>De&#x0161;kin</surname><given-names>Marin</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bjelinski</surname><given-names>Igor</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Juri&#x0161;i&#x0107; Er&#x017E;en</surname><given-names>Dubravka</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Krni&#x0107;</surname><given-names>Mladen</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ti&#x010D;inovi&#x0107; Kurir</surname><given-names>Tina</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Radman</surname><given-names>Maja</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mi&#x0161;ki&#x0107;</surname><given-names>Bla&#x017E;enka</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref><xref ref-type="aff" rid="aff9"><sup>9</sup></xref><xref ref-type="aff" rid="aff10"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vrkljan</surname><given-names>Milan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff11"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Canecki Var&#x017E;i&#x0107;</surname><given-names>Silvija</given-names></name><xref ref-type="aff" rid="aff10"><sup>10</sup></xref><xref ref-type="aff" rid="aff12"><sup>12</sup></xref></contrib>
<aff id="aff1"><label>1</label>Sveu&#x010D;ili&#x0161;na klinika za dijabetes, endokrinologiju i bolesti metabolizma Vuk Vrhovac, Klini&#x010D;ka bolnica Merkur, <addr-line>Zagreb</addr-line></aff>
<aff id="aff2"><label>2</label>Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Zagrebu</aff>
<aff id="aff3"><label>3</label>Bolni&#x010D;ka ljekarna, Op&#x0107;a bolnica &#x0160;ibensko kninske &#x017E;upanije, <addr-line>&#x0160;ibenik</addr-line></aff>
<aff id="aff4"><label>4</label>Zavod za endokrinologiju, dijabetologiju i bolesti metabolizma, Klinika za unutarnje bolesti, Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Rijeci, KBC Rijeka</aff>
<aff id="aff5"><label>5</label>Odjel za endokrinologiju, dijabetes i bolesti metabolizma, Klinika za unutarnje bolesti Medicinskog fakulteta u Zagrebu, KB Sveti Duh, <addr-line>Zagreb</addr-line></aff>
<aff id="aff6"><label>6</label>Op&#x0107;a bolnica Bjelovar</aff>
<aff id="aff7"><label>7</label>Zavod za endokrinologiju, dijabetologiju i bolesti metabolizma, Klinika za unutarnje bolesti, Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Splitu, KBC Split</aff>
<aff id="aff8"><label>8</label>Odjel za gastroenterologiju, endokrinologiju i dijabetologiju, Op&#x0107;a bolnica &#x201E;Dr. Josip Ben&#x010D;evi&#x0107;&#x201C;, Slavonski Brod</aff>
<aff id="aff9"><label>9</label>Medicinski fakultet Sveu&#x010D;ili&#x0161;ta Josipa Jurja Strossmayera, <addr-line>Osijek</addr-line></aff>
<aff id="aff10"><label>10</label>Fakultet za dentalnu medicinu i zdravstvo Sveu&#x010D;ili&#x0161;ta Josipa Jurja Strossmayera, <addr-line>Osijek</addr-line></aff>
<aff id="aff11"><label>11</label>Zavod za endokrinologiju, dijabetes i bolesti metabolizma Mladen Sekso, Klinika za unutarnje bolesti Medicinskog fakulteta u Zagrebu, KBC Sestre milosrdnice, <addr-line>Zagreb</addr-line></aff>
<aff id="aff12"><label>12</label>Zavod za endokrinologiju, Klinika za unutarnje bolesti Medicinskog fakulteta u Osijeku, KBC Osijek</aff>
</contrib-group>
<author-notes><corresp id="cor1">Adresa za dopisivanje: Doc. dr. sc. Dario Raheli&#x0107;, <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-2901-0646">https://orcid.org/0000-0002-2901-0646</ext-link> Sveu&#x010D;ili&#x0161;na klinika za dijabetes, endokrinologiju i bolesti metabolizma Vuk Vrhovac, KB Merkur, Dugi dol 4a, 10000 Zagreb; e-po&#x0161;ta: <email xlink:href="dario.rahelic@kb-merkur.hr">dario.rahelic@kb-merkur.hr</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>05</month><year>2020</year></pub-date>
<volume>142</volume>
<issue>3-4</issue>
<fpage>85</fpage>
<lpage>88</lpage>
<permissions>
<copyright-year>2020</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<p>Radna skupina Hrvatskog dru&#x0161;tva za dijabetes i bolesti metabolizma Hrvatskoga lije&#x010D;ni&#x010D;kog zbora pripremila je smjernice za postupanje u pandemiji COVID-19 za osobe sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u i za zdravstvene djelatnike. U preporukama su nagla&#x0161;eni razmjeri pandemije i mogu&#x0107;e posljedice za oboljele od &#x0161;e&#x0107;erne bolesti. Opisana je klini&#x010D;ka slika i ponovljene smjernice Nacionalnog sto&#x017E;era civilne za&#x0161;tite kako se osobe od &#x0161;e&#x0107;erne bolesti mogu za&#x0161;tititi i &#x0161;to trebaju &#x010D;initi za dobru regulaciju glikemije. Predlo&#x017E;ene su mjere koje trebaju provoditi zdravstvene ustanove koje skrbe o bolesnicima sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u i na&#x010D;ela zbrinjavanja glikemije u hitnom prijemu i tijekom hospitalizacije.</p>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>The Working group of the Croatian Society for Diabetes and Metabolic Disorders of the Croatian Medical Association has prepared recommendations for people with diabetes and healthcare professionals in the age of COVID-19 pandemic. The recommendations emphasized the scale of the pandemic and the possible consequences for those suffering from diabetes. Enclosed are clinical presentation and directions of the National civil protection headquarters on the methods that enable people with diabetes to protect themselves, and maintain their blood glucose in target range as well. Measures have been proposed to be implemented by healthcare facilities that deliver care for patients with diabetes, and the principles of glycemic control in emergency department and during hospitalization.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori INFEKCIJE KORONAVIRUSOM &#x2013; komplikacije, prevencija</kwd><kwd>PANDEMIJA</kwd><kwd>KOMORBIDITET</kwd><kwd>&#x0160;E&#x0106;ERNA BOLEST,TIP 1 &#x2013; komplikacije, lije&#x010D;enje</kwd><kwd>&#x0160;E&#x0106;ERNA BOLEST,TIP 2 &#x2013; komplikacije, lije&#x010D;enje</kwd><kwd>&#x0160;E&#x0106;ER U KRVI &#x2013; analiza</kwd><kwd>SAMOZA&#x0160;TITA &#x2013; metode</kwd><kwd>ZDRAVSTVENI DJELATNICI</kwd><kwd>SMJERNICE</kwd><kwd>HRVATSKA</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>CORONAVIRUS INFECTIONS &#x2013; complications, prevention and control</kwd><kwd>PANDEMICS</kwd><kwd>COMORBIDITY</kwd><kwd>DIABETES MELLITUS,TYPE 1 &#x2013; complications, therapy</kwd><kwd>DIABETES MELLITUS,TYPE 2 &#x2013; complications, therapy</kwd><kwd>BLOOD GLUCOSE &#x2013; analysis</kwd><kwd>SELF CARE &#x2013; methods</kwd><kwd>HEALTH PERSONNEL</kwd><kwd>PRACTICE GUIDELINES AS TOPIC</kwd><kwd>CROATIA</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>COVID-19 (coronavirus disease 2019) je zarazna bolest pandemijskih razmjera koja je po&#x010D;ela u Wuhanu (Kina) u prosincu 2019. godine. Uzrokovana je koronavirusom (SARS-CoV-2, tj. severe acute respiratory syndrome coronavirus 2) i predstavlja ozbiljnu prijetnju za zdravlje, ponajvi&#x0161;e kod osoba s pridru&#x017E;enim bolestima. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>&#x2013;<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) Starije osobe i osobe s pridru&#x017E;enim kroni&#x010D;nim bolestima poput &#x0161;e&#x0107;erne bolesti, arterijske hipertenzije i kardiovaskularnih bolesti pripadaju posebno rizi&#x010D;noj populaciji za razvoj te&#x017E;eg oblika bolesti. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>&#x2013;<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>)</p>
<p>Radna skupina Hrvatskog dru&#x0161;tva za dijabetes i bolesti metabolizma Hrvatskoga lije&#x010D;ni&#x010D;kog zbora pripremila je smjernice za osobe sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u i zdravstvene djelatnike koji skrbe o oboljelima od &#x0161;e&#x0107;erne bolesti u Republici Hrvatskoj uzimaju&#x0107;i u obzir preporuke Me&#x0111;unarodne dijabeti&#x010D;ke federacije, Ameri&#x010D;kog dijabetolo&#x0161;kog dru&#x0161;tva, Kanadskoga dijabetolo&#x0161;kog dru&#x0161;tva, Diabetes UK i Svjetske zdravstvene organizacije. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>&#x2013;<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>)</p>
<sec sec-type="other1">
<title>Simptomi</title>
<p>Prema podatcima iz Kine prosje&#x010D;no vrijeme inkubacije je 5,2 dana (95% CI 4,1&#x2013;7,0) s 95% distribucije kroz 12,5 dana. (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>) Naj&#x010D;e&#x0161;&#x0107;i simptomi bolesti COVID-19 su vru&#x0107;ica, suhi ka&#x0161;alj, kratak dah i osje&#x0107;aj umora. Neki pacijenti mogu imati i bolove u mi&#x0161;i&#x0107;ima, hunjavicu, grlobolju, za&#x010D;epljenost nosa, bol u trbuhu, povra&#x0107;anje ili proljev. U ve&#x0107;ine osoba bolest ima bla&#x017E;i oblik, a treba napomenuti i da dio zara&#x017E;enih osoba ima asimptomatski tijek. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r2"><italic>2</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>&#x2013;<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>)</p>
</sec>
<sec sec-type="other2">
<title>COVID-19 i &#x0161;e&#x0107;erna bolest</title>
<p>Iako su osobe sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u sklonije infekcijama, za sada nema dokaza da imaju ve&#x0107;u vjerojatnost zaraziti se virusom COVID-19 od ostatka populacije. Tako&#x0111;er, prema dostupnim podatcima mogu&#x0107;nost zaraze virusom COVID-19 jednaka je u osoba s tipom 1 i tipom 2 &#x0161;e&#x0107;erne bolesti. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) Me&#x0111;utim, COVID-19 mo&#x017E;e poprimiti ozbiljniju klini&#x010D;ku sliku u osoba sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u koje su podlo&#x017E;nije i &#x010D;e&#x0161;&#x0107;em razvoju komplikacija, kao i smrtnom ishodu. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>, <xref ref-type="bibr" rid="r8"><italic>8</italic></xref>&#x2013;<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Prema dostupnoj literaturi &#x010D;ini se da je rizik od komplikacija manji ako je &#x0161;e&#x0107;erna bolest dobro regulirana i izjedna&#x010D;uje se s ostatkom populacije. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>)</p>
</sec>
<sec sec-type="other3">
<title>Preporuke</title>
<p>Kako osoba sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u mo&#x017E;e za&#x0161;tititi sebe i druge osobe od COVID-19?</p>
<p>Iznimno je va&#x017E;no pridr&#x017E;avati se uputa Nacionalnog sto&#x017E;era civilne za&#x0161;tite vezane uz koronavirus, a osobito se nagla&#x0161;ava:</p>
<list id="L1" list-type="simple"><list-item><p>poku&#x0161;ati smanjiti socijalne kontakte, grupiranje, dr&#x017E;ati distancu od 2 m, izbjegavati kontakt sa svakim tko pokazuje znakove respiratorne bolesti (npr. ka&#x0161;alj);</p></list-item>
<list-item><p>prekriti usta i nos maramicom prilikom ka&#x0161;ljanja ili kihanja;</p></list-item>
<list-item><p>redovito i temeljito prati ruke sapunom i vodom najmanje 20 sekundi;</p></list-item>
<list-item><p>koristiti sredstva za dezinfekciju ruku, odnosno teku&#x0107;ine s vi&#x0161;e od 60% alkohola;</p></list-item>
<list-item><p>izbjegavati dodirivanje lica, o&#x010D;iju, nosa i usta;</p></list-item>
<list-item><p>izbjegavati dodirivanje &#x010D;esto kori&#x0161;tenih povr&#x0161;ina (kvake, tipkala, vodilice itd.);</p></list-item>
<list-item><p>&#x010D;istiti i dezinficirati povr&#x0161;ine koje se dodiruju.</p></list-item></list>
<boxed-text id="ba"><caption><title>Kako se osoba sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u treba pripremiti za slu&#x010D;aj obolijevanja od COVID-19?</title></caption>
<table-wrap position="float">
<table frame="hsides" rules="groups">
<col width="100%"/>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt"><bold>ako ima simptome respiratorne bolesti ili gripi sli&#x010D;ne simptome, ostati kod ku&#x0107;e u izolaciji, osim u slu&#x010D;aju potrebe posjete lije&#x010D;niku</bold></td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">kontaktirati svog obiteljskog lije&#x010D;nika, odnosno po potrebi dijabetologa i ne pani&#x010D;ariti</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">osigurati odgovaraju&#x0107;u koli&#x010D;inu lijekova i trakica, odnosno senzora za kontrolu glikemije kao i trakica za odre&#x0111;ivanje ketona u krvi</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">pripremiti zalihu jednostavnih ugljikohidrata (za&#x0161;e&#x0107;erena bezalkoholna pi&#x0107;a, med, keksi ili &#x0161;e&#x0107;erni bomboni) za slu&#x010D;aj hipoglikemije; u slu&#x010D;aju hipoglikemije, preporu&#x010D;uje se uzeti 15 grama ugljikohidrata u navedenom obliku te nakon 15 minuta provjeriti vrijednost glukoze u plazmi</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">osigurati dovoljan unos teku&#x0107;ine i dodatno paziti na prehranu, redovito uzimati terapiju</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">primjenjivati &#x201E;pravila za dane bolesti&#x201D; koja se ina&#x010D;e koriste u akutnoj bolesti, gripi i drugim infekcijama</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">osigurati GlucaGen HypoKit za slu&#x010D;aj te&#x0161;ke hipoglikemije i podu&#x010D;iti &#x010D;lanove obitelji odnosno uku&#x0107;ane kako ga primijeniti ako do sada nisu educirani</td>
</tr>
<tr>
<td valign="middle" align="justify" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">u slu&#x010D;aju pojave ugro&#x017E;avaju&#x0107;ih znakova kao &#x0161;to su ote&#x017E;ano disanje ili kratko&#x0107;a daha, uporna bol i pritisak u prsima, zbunjenost ili nemogu&#x0107;nost odgovora, plavkaste usne ili lice, uputa za uku&#x0107;ane &#x2013; pozvati hitnu medicinsku pomo&#x0107;</td>
</tr>
</tbody></table></table-wrap></boxed-text>
<boxed-text id="bb"><caption><title>Pravila za dane bolesti (engl. <italic>Sick day rules</italic>):</title></caption>
<table-wrap position="float">
<table frame="hsides" rules="groups">
<col width="100%"/>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">S (engl. <italic>Sugar</italic>): provjeravati glikemiju svakih dva do tri sata ili &#x010D;e&#x0161;&#x0107;e i korigirati ako su visoke vrijednosti glikemije.</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">I (engl. <italic>Insulin</italic>): uvijek nastaviti primjenjivati inzulin, unato&#x010D; bolesti, kako bi se izbjegla dijabeti&#x010D;ka ketoacidoza; vjerojatno &#x0107;e biti potrebne ve&#x0107;e doze inzulina nego &#x0161;to je uobi&#x010D;ajeno.</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">C (engl. <italic>Carbs</italic>): osigurati unos ugljikohidrata i piti dosta teku&#x0107;ine (30 do 100 ml/sat). Ako je glikemija visoka, piti teku&#x0107;inu bez ugljikohidrata, a ako je niska, piti teku&#x0107;inu s ugljikohidratima.</td>
</tr>
<tr>
<td valign="middle" align="justify" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">K (engl. <italic>Ketones</italic>): provjeravati ketone u krvi ili urinu svaka &#x010D;etiri sata. Ako su ketoni prisutni, uzeti brzodjeluju&#x0107;i inzulin. Piti puno vode kako bi se ketoni izlu&#x010D;ili iz organizma.</td>
</tr>
</tbody></table></table-wrap></boxed-text>
<p>Ako su, unato&#x010D; primijenjenoj terapiji, i dalje prisutne povi&#x0161;ene vrijednosti glikemije, potrebno je telefonski kontaktirati obiteljskog lije&#x010D;nika koji &#x0107;e dati daljnje upute.</p>
<p>Tako&#x0111;er, u slu&#x010D;aju da mjere korekcije terapije i prehrane ne rezultiraju pobolj&#x0161;anjem regulacije glikemije, svakako je potrebno razmotriti mogu&#x0107;nost da je druga akutna bolest u podlozi hiperglikemije, o &#x010D;emu osoba sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u treba raspraviti s obiteljskim lije&#x010D;nikom ili dijabetologom.</p>
<boxed-text id="bc"><caption><title>&#x0160;to trebaju u&#x010D;initi zdravstvene ustanove koje skrbe o bolesnicima sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u?</title></caption>
<table-wrap position="float">
<table frame="hsides" rules="groups">
<col width="100%"/>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">strogo kontrolirati ulaz i kretanje bolesnika u prostorima zdravstvene ustanove</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">rutinske dijabetolo&#x0161;ke kontrole trebalo bi izbjegavati, a vrijeme zadr&#x017E;avanja oboljelih u &#x010D;ekaonicama &#x0161;to je vi&#x0161;e mogu&#x0107;e skratiti</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">osigurati mogu&#x0107;nost elektroni&#x010D;kih konzultacija lije&#x010D;nika obiteljske medicine s dijabetologom, pomo&#x0107;u A5 uputnica</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">osigurati oboljelima od &#x0161;e&#x0107;erne bolesti mogu&#x0107;nost telefonske odnosno elektroni&#x010D;ke konzultacije s dijabetologom u slu&#x010D;aju hitnosti</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">skratiti vrijeme trajanja hospitalizacije gdje god je to mogu&#x0107;e</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">zadr&#x017E;ati &#x0161;to ve&#x0107;u funkcionalnost skrbi o trudnicama i osobama s aktivnim dijabeti&#x010D;kim stopalom</td>
</tr>
<tr>
<td valign="middle" align="justify" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">s obzirom na o&#x010D;ekivanja da &#x0107;e udio bolesnika sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u nadma&#x0161;iti uobi&#x010D;ajenih 18% hospitaliziranih, potrebno je organizirati jasne i prakti&#x010D;ne smjernice za zbrinjavanje glikemije u bolni&#x010D;kim uvjetima od strane svih specijalnosti</td>
</tr>
</tbody></table></table-wrap></boxed-text>
<boxed-text id="bd"><caption><title>Preporuke za osobe sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u tipa 1</title></caption>
<table-wrap position="float">
<table frame="hsides" rules="groups">
<col width="100%"/>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">glukoza &lt;3,9 mmol/L &#x2013; smanjiti dozu brzodjeluju&#x0107;eg inzulina, u slu&#x010D;aju povra&#x0107;anja kontaktirati lije&#x010D;nika</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">glukoza 4,0&#x2013;16,0 mmol/L, ketoni u krvi &lt;0,6 mmol/L &#x2013; nastaviti uobi&#x010D;ajene doze inzulina</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">glukoza 4,0&#x2013;16,0 mmol/L, ketoni u krvi &#x2265;0,6 mmol/L &#x2013; pove&#x0107;ati dozu brzodjeluju&#x0107;eg inzulina 10%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">glukoza &gt;16 mmol/L, ketoni u krvi 0,7&#x2013;1,4 mmol/L &#x2013; pove&#x0107;ati doze brzodjeluju&#x0107;eg inzulina 15%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">glukoza &gt;16 mmol/L, ketoni u krvi 1,5&#x2013;3,0 mmol/L &#x2013; pove&#x0107;ati doze brzodjeluju&#x0107;eg inzulina 20%</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">uvijek se javiti lije&#x010D;niku ako oboljela osoba nije sigurna &#x0161;to treba u&#x010D;initi, ako povra&#x0107;a i ne mo&#x017E;e uzimati ni&#x0161;ta na usta dulje od 6 sati, ako je glukoza visoka dulje od 24 sata te ako razvije simptome i znakove dijabeti&#x010D;ke ketoacidoze</td>
</tr>
<tr>
<td valign="middle" align="justify" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">osobe sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u koje koriste inzulinske pumpe, u slu&#x010D;aju tehni&#x010D;kog kvara inzulinske pumpe trebaju kontaktirati dijabetologa i tehni&#x010D;ku podr&#x0161;ku tvrtke zastupnika inzulinske pumpe u Republici Hrvatskoj; u slu&#x010D;aju nemogu&#x0107;nosti otklona kvara, uvesti intenziviranu inzulinsku terapiju</td>
</tr>
</tbody></table></table-wrap></boxed-text>
<boxed-text id="be"><caption><title>Preporuke za osobe sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u tipa 2</title></caption>
<table-wrap position="float">
<table frame="hsides" rules="groups">
<col width="100%"/>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">u slu&#x010D;aju te&#x017E;e infekcije ili dehidracije potrebno je privremeno izostaviti metformin i SGLT-2 inhibitore, kontaktirati nadle&#x017E;nog lije&#x010D;nika radi korekcije terapije</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">ako primaju inzulin, a glukoza &gt;10 mmol/L, potrebno je postupno pove&#x0107;avati dozu inzulina za 2&#x2013;3 j. uz &#x010D;e&#x0161;&#x0107;a testiranja, najmanje svaka 4 sata, a jo&#x0161; &#x010D;e&#x0161;&#x0107;e ako je &gt;15 mmol/L, tada provjeriti ketone u krvi pomo&#x0107;u trakice</td>
</tr>
<tr>
<td valign="middle" align="justify" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">ako su ketoni u krvi pozitivni kontaktirati lije&#x010D;nika</td>
</tr>
</tbody></table></table-wrap></boxed-text>
</sec>
<sec sec-type="other4">
<title>Preporuke za skrb osoba sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u u hitnoj slu&#x017E;bi ili tijekom hospitalizacije</title>
<p>U hitnoj slu&#x017E;bi obvezno tra&#x017E;iti podatke o prisutnosti &#x0161;e&#x0107;erne bolesti i to&#x010D;an popis terapije koju pacijent uzima (to&#x010D;ni nazivi i doze lijekova, osobito inzulina, u&#x010D;estalost i vremena primjene). Preporu&#x010D;uje se izostaviti lijekove kod kojih je rizi&#x010D;na primjena uz stanje dehidracije, hipoksemije, pogor&#x0161;ane bubre&#x017E;ne funkcije, hipotenzije ili hipoperfuzije (metformin, SGLT-2 inhibitori i starija generacija derivata sulfonilureje).</p>
<p>Zbog velikog broja za&#x0161;ti&#x0107;enih naziva lijekova i mogu&#x0107;nosti kombinacija, preporu&#x010D;uje se imati pripremljenu listu navedenih preparata.</p>
<p>Kod klini&#x010D;ki nestabilnih pacijenata i osoba sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u tipa 1 potrebno je primijeniti inzulinsku terapiju te pripremiti razumljive algoritme o doziranju inzulina i kontrolama glukoze u plazmi. Klini&#x010D;ki stabilni pacijenti kojima je samo potrebna izolacija mogu nastaviti uobi&#x010D;ajenu terapiju. &#x010C;im klini&#x010D;ko stanje dozvoljava, vratiti prethodnu antihiperglikemijsku terapiju, ako je osiguravala zadovoljavaju&#x0107;u glukoregulaciju.</p>
</sec>
<sec sec-type="other5">
<title>Zaklju&#x010D;ak</title>
<p>Veli&#x010D;ina i ozbiljnost prijetnje pandemije COVID-19, osobito starijim osobama kao i onima sa zna&#x010D;ajnim komorbiditetima, pokrenule su do sada nevi&#x0111;ene javnozdravstvene mjere i munjevitu reorganizaciju &#x010D;itavoga zdravstvenog sustava i raspolo&#x017E;ivih resursa radi postizanja maksimalno u&#x010D;inkovitog odgovora na aktualnu ugrozu, sve u cilju o&#x010D;uvanja zdravlja i &#x017E;ivota svih gra&#x0111;ana. Prevalencija &#x0161;e&#x0107;erne bolesti (9%), njezina udru&#x017E;enost s komorbiditetima i povezanost s rizikom od COVID-19 i klini&#x010D;kim nepovoljnim ishodima nagla&#x0161;avaju va&#x017E;nost nastavka pru&#x017E;anja skrbi osobama sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u u zna&#x010D;ajno promijenjenim okolnostima. Stoga smo predlo&#x017E;ili okvire rje&#x0161;enja kojima se pru&#x017E;atelji zdravstvene za&#x0161;tite mogu voditi ovisno o postoje&#x0107;im mogu&#x0107;nostima. Nagla&#x0161;ava se va&#x017E;nost pridr&#x017E;avanja uputa Nacionalnog sto&#x017E;era civilne za&#x0161;tite i primjena pravila pona&#x0161;anja u danima bolesti za osobe sa &#x0161;e&#x0107;ernom bole&#x0161;&#x0107;u.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Izrada smjernica nije financijski potpomognuta.</p>
<p>Guidelines development was not supported financially.</p>
</fn>
</fn-group>
<ack>
<title>Zahvala</title>
<p>Autori zahvaljuju Anni Duspara iz Klini&#x010D;ke bolnice Merkur na pomo&#x0107;i prilikom tehni&#x010D;ke pripreme smjernica.</p>
</ack>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><etal/></person-group> <article-title>A new coronavirus associated with human respiratory disease in China.</article-title> <source>Nature</source>. <year>2020</year>;<volume>579</volume>:<fpage>265</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmid">32015508</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>F</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group>. <article-title>Coronavirus Disease 2019: What we know?</article-title> <source>J Med Virol</source>. <year>2020</year>;<volume>&#x2022;&#x2022;&#x2022;</volume>:<fpage>719</fpage>&#x2013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">32170865</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><article-title>The 2019-nCoV Outbreak Joint Field Epidemiology Investigation Team, Li Q. Notes from the field: an outbreak of NCIP (2019-nCoV) infection in China &#x2014; Wuhan, Hubei Province, 2019&#x2013;2020.</article-title> <source>China CDC Weekly</source>. <year>2020</year>;<volume>2</volume>:<fpage>79</fpage>&#x2013;<lpage>80</lpage>.</mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>WJ</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>XJ</given-names></name><etal/></person-group> <article-title>A novel coronavirus genome identified in a cluster of pneumonia cases &#x2014; Wuhan, China 2019&#x2013;2020.</article-title> <source>China CDC Weekly</source>. <year>2020</year>;<volume>2</volume>:<fpage>61</fpage>&#x2013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.46234/ccdcw2020.017</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><etal/></person-group> <article-title>A novel coronavirus from patients with pneumonia in China, 2019.</article-title> <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>727</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmid">31978945</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Misra</surname><given-names>A</given-names></name></person-group>. <article-title>Clinical considerations for patients with diabetes in times of COVID-19 epidemic.</article-title> <source>Diabetes Metab Syndr</source>. <year>2020</year>;<volume>14</volume>:<fpage>211</fpage>&#x2013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/j.dsx.2020.03.002</pub-id><pub-id pub-id-type="pmid">32172175</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMichael</surname><given-names>TM</given-names></name><name><surname>Currie</surname><given-names>DW</given-names></name><name><surname>Clark</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington.</article-title> <source>N Engl J Med</source>. <year>2020</year>;<volume>&#x2022;&#x2022;&#x2022;</volume>:<fpage>2005</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2005412</pub-id><pub-id pub-id-type="pmid">32220208</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group> <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.</article-title> <source>Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>497</fpage>&#x2013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group>. <article-title>Clinical predictors of mortality due to COVID-19 based on ananalysis of data of 150 patients from Wuhan, China.</article-title> <source>Intensive Care Med</source>. <year>2020</year>; <comment>Epub ahead of print</comment></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>WJ</given-names></name><name><surname>Ni</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group> <article-title>Clinical Characteristics of Coronavirus Disease 2019 in China.</article-title> <source>N Engl J Med</source>. <year>2020</year>; <comment>Epub ahead of print</comment> <pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><etal/></person-group> <article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.</article-title> <source>Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>507</fpage>&#x2013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id><pub-id pub-id-type="pmid">32007143</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="web">International Diabetes Federation. COVID-19 outbreak: guidance for people with diabetes. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-forpeople-with-diabetes.html">https://www.idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-forpeople-with-diabetes.html</ext-link>. Pristupljeno 6. travnja 2020.</mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="web">American Diabetes Association. COVID-19 (Coronavirus). Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.diabetes.org/coronavirus-covid-19">https://www.diabetes.org/coronavirus-covid-19</ext-link>. Pristupljeno 6. travnja 2020.</mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="web">Diabetes Canada. FAQ about COVID-19 and diabetes. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.diabetes.ca/en-CA/resources/tools---resources/faq-about-covid-19-and-diabetes">https://www.diabetes.ca/en-CA/resources/tools---resources/faq-about-covid-19-and-diabetes</ext-link>. Pristupljeno 6. travnja 2020.</mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="web">Diabetes UK. Updates: Coronavirus and diabetes. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.diabetes.org.uk/about_us/news/coronavirus">https://www.diabetes.org.uk/about_us/news/coronavirus</ext-link>. Pristupljeno 6. travnja 2020.</mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="web">WHO. Coronavirus disease (COVID-19) Pandemic. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</ext-link>. Pristupljeno 6. travnja 2020.</mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><etal/></person-group> <article-title>Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.</article-title> <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>1199</fpage>&#x2013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001316</pub-id><pub-id pub-id-type="pmid">31995857</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
